Globally, the leading cause of maternal death is postpartum hemorrhage (PPH). In the absence of a skilled birth attendant, the World Health Organization recommends that a uterotonic drug, preferably oxytocin, be given to prevent PPH. This fact sheet describes how oxytocin in the Uniject™ injection system is one of the tools that programs in Latin America can use to expand access to oxytocin for prevention and treatment of PPH.
Corporate author(s): PATH
Publication date: September 2011
154 KB PDF
Hard copies are not available.
Some digital files may be saved at low resolutions to conserve file size. Versions with higher quality may be available; see the contact information below to enquire.
Region: Latin America
For more information…
Contact: PATH Publications
Mailing address: PATH, PO Box 900922, Seattle, WA 98109 USA